# Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

> **NCT07594119** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Rapport Therapeutics Inc.** · enrollment: 312 (estimated)

## Conditions studied

- Focal Seizure
- Epilepsy
- Focal Epilepsy

## Interventions

- **DRUG:** RAP-219
- **DRUG:** RAP-219
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07594119
- **Lead sponsor:** Rapport Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2029-07
- **Final completion:** 2029-09
- **Target enrollment:** 312 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07594119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07594119, "Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures". Retrieved via AI Analytics 2026-08-16 from https://api.ai-analytics.org/clinical/NCT07594119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*